U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H16N4O3
Molecular Weight 348.3553
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PI-103

SMILES

OC1=CC=CC(=C1)C2=NC(N3CCOCC3)=C4OC5=NC=CC=C5C4=N2

InChI

InChIKey=TUVCWJQQGGETHL-UHFFFAOYSA-N
InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2

HIDE SMILES / InChI

Molecular Formula C19H16N4O3
Molecular Weight 348.3553
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P42336
Gene ID: 5290.0
Gene Symbol: PIK3CA
Target Organism: Homo sapiens (Human)
0.002 µM [IC50]
Target ID: P42338
Gene ID: 5291.0
Gene Symbol: PIK3CB
Target Organism: Homo sapiens (Human)
0.003 µM [IC50]
Target ID: O00329
Gene ID: 5293.0
Gene Symbol: PIK3CD
Target Organism: Homo sapiens (Human)
0.003 µM [IC50]
Target ID: P48736
Gene ID: 5294.0
Gene Symbol: PIK3CG
Target Organism: Homo sapiens (Human)
0.015 µM [IC50]
Target ID: P42345
Gene ID: 2475.0
Gene Symbol: MTOR
Target Organism: Homo sapiens (Human)
0.03 µM [IC50]
Target ID: P78527|||Q9UME3
Gene ID: 5591.0
Gene Symbol: PRKDC
Target Organism: Homo sapiens (Human)
0.023 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Synthesis and biological evaluation of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors.
2007 May 1
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
2010 Apr 1
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
2010 Dec
Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.
2010 Mar 26
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption.
2010 Oct
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
2011 Oct 30
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
2013 Apr 15
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:59:53 GMT 2023
Edited
by admin
on Sat Dec 16 09:59:53 GMT 2023
Record UNII
YQX02F616F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PI-103
Common Name English
PHENOL, 3-(4-(4-MORPHOLINYL)PYRIDO(3',2':4,5)FURO(3,2-D)PYRIMIDIN-2-YL)-
Systematic Name English
PIK-103
Code English
Code System Code Type Description
CAS
371935-74-9
Created by admin on Sat Dec 16 09:59:53 GMT 2023 , Edited by admin on Sat Dec 16 09:59:53 GMT 2023
PRIMARY
FDA UNII
YQX02F616F
Created by admin on Sat Dec 16 09:59:53 GMT 2023 , Edited by admin on Sat Dec 16 09:59:53 GMT 2023
PRIMARY
PUBCHEM
9884685
Created by admin on Sat Dec 16 09:59:53 GMT 2023 , Edited by admin on Sat Dec 16 09:59:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID40190676
Created by admin on Sat Dec 16 09:59:53 GMT 2023 , Edited by admin on Sat Dec 16 09:59:53 GMT 2023
PRIMARY
CHEBI
90524
Created by admin on Sat Dec 16 09:59:53 GMT 2023 , Edited by admin on Sat Dec 16 09:59:53 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY